NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

HROW

Harrow Inc

Jun 30 • 04:00PM ET

30.54

Dollar change -0.34
Percentage change -1.10	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Peers: OCUL EYPT PRPH AKTX ALDX EDIT QURE TTOO CRSP BNGO

| Held by: VTI IWM VXF IWO SCHA VTWO VHT IHE XPH IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.61	Insider Own	16.01%	Shs Outstand	35.65M	Perf Week	-1.48%
Market Cap	1.12B	Forward P/E	21.01	EPS next Y	1.45	Insider Trans	-1.43%	Shs Float	30.83M	Perf Month	12.28%
Enterprise Value	1.28B	PEG	-	EPS next Q	0.01	Inst Own	56.54%	Short Float	13.18%	Perf Quarter	16.52%
Income	-21.70M	P/S	5.27	EPS this Y	128.75%	Inst Trans	-0.92%	Short Ratio	8.36	Perf Half Y	-9.73%
Sales	212.86M	P/B	19.29	EPS next Y	931.86%	ROA	-6.58%	Short Interest	4.06M	Perf YTD	-8.97%
Book/sh	1.58	P/C	16.80	EPS next 5Y	-	ROE	-37.23%	52W High	59.23 -48.44%	Perf Year	43.11%
Cash/sh	1.82	P/FCF	2668.57	EPS past 3/5Y	10.79% -	ROIC	-12.22%	52W Low	20.36 50.03%	Perf 3Y	376.44%
Dividend Est.	-	EV/EBITDA	61.01	Sales past 3/5Y	40.17% 31.29%	Gross Margin	74.53%	Volatility	3.61% 5.05%	Perf 5Y	448.29%
Dividend TTM	-	EV/Sales	6.03	EPS Y/Y TTM	33.18%	Oper. Margin	2.24%	ATR (14)	1.46	Perf 10Y	272.89%
Dividend Ex-Date	-	Quick Ratio	0.85	Sales Y/Y TTM	53.49%	Profit Margin	-10.19%	RSI (14)	54.46	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.91	EPS Q/Q	-29.79%	SMA20	-0.31%	Beta	0.41	Target Price	56.89
Payout	-	Debt/Eq	4.07	Sales Q/Q	38.29%	SMA50	10.81%	Rel Volume	0.90	Prev Close	30.88
Employees	382	LT Debt/Eq	2.14	Earnings	May 08 AMC	SMA200	-11.67%	Avg Volume	486.24K	Price	30.54
IPO	Apr 24, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	-986.96% -16.08%	Trades		Volume	438,801	Change	-1.10%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-12-25	Initiated	BTIG Research	Buy	$62
Jun-10-25	Initiated	William Blair	Outperform
Feb-06-25	Initiated	H.C. Wainwright	Buy	$57
Dec-04-24	Reiterated	B. Riley Securities	Buy	$73 → $69
Apr-11-24	Initiated	Craig Hallum	Buy	$24
Sep-08-22	Resumed	B. Riley Securities	Buy	$17
Oct-14-21	Resumed	B. Riley Securities	Buy	$16
Sep-24-21	Initiated	Aegis Capital	Buy	$15
Jul-02-21	Initiated	Ladenburg Thalmann	Buy	$14.25

Jun-18-25 07:00AM	Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications (Business Wire)
Jun-09-25 07:00AM	Harrow Acquires U.S. Commercial Rights to BYQLOVI (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals (Business Wire)
May-14-25 10:07AM	Jim Cramer on Harrow, Inc. (HROW) - "Eye Care's a Good Biz - If It Makes Money, Don't Walk Away Pre-Breakout" (Insider Monkey)
07:00AM	Harrow to Present at Two Investor Conferences in May (Business Wire)
May-10-25 03:03AM	Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... (GuruFocus.com)
05:10PM	Loading…
May-08-25 05:10PM	Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Harrow Announces First-Quarter 2025 Financial Results (Business Wire)
09:32AM	Harrow Inc (HROW) Q1 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
May-07-25 10:28AM	What To Expect From Harrow Inc (HROW) Q1 2025 Earnings (GuruFocus.com)
May-05-25 07:00AM	Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 (Business Wire)
Apr-30-25 07:35AM	United Therapeutics (UTHR) Q1 Earnings and Revenues Top Estimates (Zacks)
Apr-29-25 07:35AM	What Recession? I'm Swimming In Dividends (Seeking Alpha)
Apr-24-25 10:00AM	NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) (PR Newswire) +5.20%
Apr-21-25 04:26PM	Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Apr-10-25 07:00AM	Harrow Expands VEVYE Access for All Program to ImprimisRxs Klarity-C Patients (Business Wire) -5.76%
04:30PM	Loading…
Mar-29-25 04:30PM	Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) (Seeking Alpha)
03:01PM	Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives (GuruFocus.com)
Mar-28-25 02:00PM	Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call (Seeking Alpha) -5.96%
01:39PM	Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (Seeking Alpha)
Mar-27-25 06:45PM	Harrow (HROW) Q4 Earnings and Revenues Top Estimates (Zacks)
04:01PM	Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results (Business Wire)
10:45AM	Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025 (Business Wire)
Mar-24-25 07:00AM	Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL (Business Wire) +5.60%
Mar-21-25 10:56PM	What To Expect From Harrow Inc (HROW) Q4 2024 Earnings (GuruFocus.com)
Mar-19-25 05:18PM	Harrow: A Name I Am Accumulating (SeekingAlpha)
Mar-17-25 04:01PM	Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance (Business Wire) +15.69%
07:00AM	Harrow Launches VEVYE Access for All (Business Wire)
Mar-11-25 07:00AM	Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE (Business Wire)
Mar-03-25 07:15AM	Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025 (Business Wire) -8.73%
Feb-07-25 09:40AM	Reddit initiated, Cigna downgraded: Wall Streets top analyst calls (TipRanks)
07:30AM	Loading…
Jan-27-25 07:30AM	Harrow Partners with Cencora to Launch Harrow Cares Program, Making IHEEZO and TRIESENCE More Accessible and Affordable for Retina Specialists and Their Patients (Business Wire)
Jan-07-25 07:00AM	Harrow Appoints Amir H. Shojaei as Chief Scientific Officer (Business Wire)
Nov-21-24 07:00AM	Harrows ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc. (Business Wire)
Nov-20-24 07:00AM	Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery (Business Wire) +6.90%
Nov-15-24 07:00AM	Harrow Announces Participation in Upcoming Investor Conferences (Business Wire) -8.98%
02:06AM	Harrow Inc (HROW) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ... (GuruFocus.com)
Nov-13-24 04:34PM	Harrow Announces Third Quarter 2024 Financial Results (Business Wire) -17.26%
07:16AM	Harrow Inc (HROW) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
07:00AM	Harrow Launches Access and Affordability Program with Price Reductions for Branded Products (Business Wire)
Nov-12-24 07:00AM	Harrow Announces Market Access Wins for VEVYE (Business Wire)
Nov-07-24 07:00AM	Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrows Branded Eyecare Products (Business Wire)
Oct-31-24 07:00AM	Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024 (Business Wire)
Oct-10-24 07:00AM	Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery (Business Wire)
Oct-03-24 07:00AM	Harrow Relaunches TRIESENCE (Business Wire) +8.44%
Oct-02-24 11:10AM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey)
Sep-25-24 12:02PM	Harrow Announces Nashville Expansion (Business Wire)
Sep-03-24 07:00AM	Harrow to Present at Three Investor Conferences in September in New York (Business Wire)
Aug-07-24 04:01PM	Harrow Announces Second Quarter 2024 Financial Results (Business Wire) +54.32%
Jul-25-24 07:00AM	Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024 (Business Wire)
Jul-12-24 07:00AM	Harrow to Attend 2024 ASRS Annual Meeting (Business Wire)
Jul-09-24 07:00AM	Harrow Enters into 340B Prime Vendor Program Contract with Apexus for IHEEZO and Other Key Harrow Products (Business Wire)
Jul-02-24 11:52AM	HROW Stock Earnings: Harrow Beats EPS, Beats Revenue for Q2 2023 (InvestorPlace)
Jun-20-24 07:00AM	Harrow Provides TRIESENCE Relaunch Update (Business Wire) +12.92%
Jun-07-24 06:30AM	The Top 7 Growth Stocks to Buy and Hold Until 2030 (InvestorPlace)
Jun-06-24 08:00AM	Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery (Business Wire)
Jun-05-24 07:00AM	Harrow Announces 52-Week Data from VEVYE ESSENCE-2 Open-Label Extension Study (Business Wire)
May-15-24 07:00AM	Harrow to Present at Two Investor Conferences in May (Business Wire)
May-13-24 08:55PM	HROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) +34.55%
04:25PM	Harrow Health Q1 Core Net Loss Widens, Revenue Increases -- Shares Rise After-Hours (MT Newswires)
04:01PM	Harrow Announces First Quarter 2024 Financial Results (Business Wire)
07:00AM	Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial (Business Wire)
Apr-25-24 07:00AM	Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024 (Business Wire)
Apr-02-24 08:16AM	Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing (Business Wire)
Mar-21-24 09:55AM	Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-19-24 09:52PM	HROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
06:51PM	Harrow Inc (HROW) Reports Substantial Revenue Growth Amidst Net Loss Expansion in 2023 (GuruFocus.com)
05:45PM	Harrow Announces Fourth Quarter and Year-End 2023 Financial Results (Business Wire)
Mar-13-24 06:35AM	Harrow (HROW) Fell on Lowering the Guidance (Insider Monkey)
Mar-05-24 07:00AM	Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024 (Business Wire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Feb-21-24 06:47AM	Heres How Harrow (HROW) Weighed on SRK Capitals Performance (Insider Monkey)
Feb-15-24 04:01PM	Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products (Business Wire)
Jan-29-24 07:00AM	Harrow Announces New Appointments to its Board of Directors (Business Wire)
Jan-11-24 07:00AM	Harrow Announces Availability of VEVYE (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease (Business Wire)
Jan-03-24 07:15AM	Melt Pharmaceuticals Provides Corporate Update (Business Wire)
07:00AM	Harrow Partners with Leading Healthcare Market Access Technology Platforms (Business Wire)
Dec-24-23 01:08PM	7 Short-Squeeze Stocks That Are Screaming for Speculation (InvestorPlace)
Nov-29-23 07:00AM	Harrow Completes Transfer of the TRIESENCE New Drug Application (Business Wire)
Nov-20-23 07:00AM	Harrow to Present at Two Investor Conferences in November (Business Wire) +5.58%
Nov-14-23 12:56PM	Harrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call Transcript (Insider Monkey) -36.01%
Nov-13-23 05:07PM	Harrow Inc (HROW) Reports 50% Revenue Growth in Q3 2023 (GuruFocus.com)
04:01PM	Harrow Announces Third Quarter 2023 Financial Results (Business Wire)
Oct-30-23 08:00AM	Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023 (Business Wire)
Oct-24-23 07:00AM	Harrow Completes Transfer of NDAs and Launches FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, and ZERVIATE in the U.S. (Business Wire)
Sep-29-23 08:00AM	Harrow Health, Inc. Changes Corporate Name to Harrow, Inc. (Business Wire)
Sep-26-23 08:00AM	Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation (Business Wire) -5.20%
Sep-21-23 01:03PM	Opaleye Management Inc. Reduces Stake in Harrow Health Inc. (GuruFocus.com)
Aug-11-23 01:05PM	Harrow Health, Inc. (NASDAQ:HROW) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 09:54AM	Q2 2023 Harrow Health Inc Earnings Call (Thomson Reuters StreetEvents) -15.45%
Aug-09-23 04:14PM	Harrow: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Harrow Announces Second Quarter 2023 Financial Results (Business Wire)
Jul-31-23 07:00AM	Harrow Launches VIGAMOX® in the U.S. (Business Wire)
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey)
Jul-26-23 03:42PM	Harrow Health inks deals for the rights to eight medications (American City Business Journals)
09:00AM	Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023 (Business Wire)
Jul-20-23 10:29AM	Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength? (Zacks)
Jul-19-23 12:17PM	Why Shares of Harrow Health Are Jumping Wednesday (Motley Fool) +17.84%
07:00AM	Harrow Prices $60 Million Public Offering of Common Stock (Business Wire)
Jul-18-23 05:00PM	Harrow Acquires Santens Branded Ophthalmic Portfolio (Business Wire)
04:05PM	Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance (Business Wire)

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Opaleye Management Inc.	10% Owner	Jun 10 '25	Sale	30.80	15,000	462,033	90,000	Jun 11 04:15 PM
Opaleye Management Inc.	10% Owner	Jun 09 '25	Sale	30.37	15,204	461,794	105,000	Jun 11 04:15 PM
Opaleye Management Inc.	10% Owner	Jun 03 '25	Sale	30.04	3,000	90,116	122,000	Jun 05 04:05 PM
Opaleye Management Inc.	10% Owner	Jun 04 '25	Sale	30.02	1,796	53,907	120,204	Jun 05 04:05 PM
Opaleye Management Inc.	10% Owner	May 12 '25	Sale	25.90	10,000	258,959	130,000	May 14 04:56 PM
Opaleye Management Inc.	10% Owner	May 13 '25	Sale	26.59	5,000	132,945	125,000	May 14 04:56 PM
BOLL ANDREW R.	Chief Financial Officer	Apr 03 '25	Option Exercise	0.00	346,500	0	914,589	Apr 07 09:55 PM
SAHAREK JOHN P.	CEO & President, ImprimisRx	Apr 03 '25	Option Exercise	0.00	277,200	0	576,863	Apr 07 09:54 PM
BAUM MARK L	Chief Executive Officer	Apr 03 '25	Option Exercise	0.00	762,300	0	2,899,825	Apr 07 09:54 PM
Opaleye Management Inc.	10% Owner	Mar 18 '25	Sale	30.01	5,000	150,055	140,000	Mar 26 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 18 '25	Sale	29.64	5,000	148,200	145,000	Mar 20 04:05 PM
Opaleye Management Inc.	10% Owner	Feb 28 '25	Sale	28.05	5,000	140,250	150,000	Mar 04 04:44 PM
Opaleye Management Inc.	10% Owner	Jan 22 '25	Sale	35.59	20,000	711,814	155,000	Jan 24 09:29 PM
SAHAREK JOHN P.	CEO of ImprimisRx	Sep 11 '24	Option Exercise	7.37	90,000	663,300	344,803	Sep 13 05:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HROW

Harrow Inc

Upgrade your FINVIZ experience